Investor Dashboard

News Releases

Date Title and Summary Additional Formats
Toggle Summary NuCana Reports First Quarter 2019 Financial Results and Provides Business Update
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom , May 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2019 and
View HTML
Toggle Summary NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference
EDINBURGH, United Kingdom , April 02, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz , Chief Financial Officer, will host one-on-one
View HTML
Toggle Summary NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom , March 07, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December
View HTML
Toggle Summary NuCana to Present at the Cowen and Company 39th Annual Health Care Conference
EDINBURGH, United Kingdom , March 05, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief
View HTML
Toggle Summary NuCana to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019
NUC-3373 Inhibits Thymidylate Synthase and Induces Endoplasmic Reticulum Stress in Colorectal Cancer Cells EDINBURGH, United Kingdom , Feb. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc ( NASDAQ:NCNA ) today announced that two abstracts related to NUC-3373 were selected for presentation at the AACR
View HTML
Toggle Summary NuCana plc Announces Withdrawal of Public Offering of ADSs
EDINBURGH, United Kingdom , Jan. 25, 2019 (GLOBE NEWSWIRE) -- NuCana plc ( Nasdaq: NCNA ), a clinical-stage biopharmaceutical company (the “Company”) focused on significantly improving treatment outcomes for patients with cancer, announced today that it has withdrawn the proposed underwritten
View HTML
Toggle Summary NuCana plc Announces Proposed Public Offering of ADSs
EDINBURGH, United Kingdom , Jan. 23, 2019 (GLOBE NEWSWIRE) -- NuCana plc ( Nasdaq: NCNA ), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it intends to sell, subject to market and other conditions, $75
View HTML
Toggle Summary NuCana to Participate in Citi's 2018 Global Healthcare Conference
EDINBURGH, United Kingdom , Nov. 28, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz , Chief Financial Officer, will host one-on-one meetings
View HTML
Toggle Summary NuCana Reports Third Quarter 2018 Financial Results and Provides Business Update
Favorable Data Presented at ESMO on NUC-1031 (Acelarin ® ) and NUC-3373 First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer Initiation of Phase III Study of Acelarin in Front-Line Advanced Biliary Tract Cancer and Phase I Study of NUC-7738 Expected by End of 2018
View HTML
Toggle Summary NuCana to Participate in the 2018 Evercore ISI HealthCONx Conference
EDINBURGH, United Kingdom , Nov. 20, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Don Munoz , Chief Financial Officer, will host one-on-one meetings at
View HTML